Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study

IntroductionAnlotinib (AL3818) is a novel multi-target tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR) and suppressing tumor growth. Modulation of tumor suppressive immune microenvironment via the inhibition of vascular endothelial growth factor may augm...

Full description

Bibliographic Details
Main Authors: Min Yuan, Zhongzheng Zhu, Wei Mao, Hui Wang, Hong Qian, Jianguo Wu, Xianling Guo, Qing Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Oncology
Subjects:
anlotinib
anti-PD-1 antibody
angiogenesis
immunotherapy
serum cytokine
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.683502/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.683502/full

Similar Items